Free tool
FAERS Monitor: Rykindo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212849 or its brand name (Rykindo, Risperidone). Reports on generic versions are filed under their own applications.
Reports
62,767
Serious
49,125
78% of reports
Hospitalization
23,613
Death reported
5,853
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- gynaecomastia9,327
- off label use5,623
- drug ineffective5,251
- weight increased4,374
- drug interaction3,244
- product use in unapproved indication2,945
- emotional disorder2,875
- abnormal weight gain2,863
- condition aggravated2,364
- somnolence2,303
- toxicity to various agents2,292
- extrapyramidal disorder2,076
- emotional distress1,957
- suicide attempt1,889
- anxiety1,829
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 400 |
| 2005 | 506 |
| 2006 | 592 |
| 2007 | 580 |
| 2008 | 698 |
| 2009 | 1,200 |
| 2010 | 1,157 |
| 2011 | 1,587 |
| 2012 | 1,884 |
| 2013 | 1,528 |
| 2014 | 1,923 |
| 2015 | 4,815 |
| 2016 | 4,930 |
| 2017 | 6,885 |
| 2018 | 4,496 |
| 2019 | 4,735 |
| 2020 | 4,062 |
| 2021 | 3,694 |
| 2022 | 3,744 |
| 2023 | 3,471 |
| 2024 | 3,566 |
| 2025 | 3,578 |
| 2026 | 2,735 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,991,392 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| gynaecomastiaSignal | 9,327 | 144.1 | 140.9 | 927,739 |
| abnormal weight gainSignal | 2,863 | 100.8 | 96.7 | 217,369 |
| emotional disorderSignal | 2,875 | 34.4 | 33.1 | 84,548 |
| extrapyramidal disorderSignal | 2,076 | 30.5 | 29.2 | 54,277 |
| suicide attemptSignal | 1,889 | 10.7 | 10.3 | 16,209 |
| drug interactionSignal | 3,244 | 7.0 | 6.7 | 16,380 |
| weight increasedSignal | 4,374 | 6.7 | 6.5 | 20,826 |
| emotional distressSignal | 1,957 | 5.5 | 5.3 | 7,105 |
| toxicity to various agentsSignal | 2,292 | 4.6 | 4.4 | 6,425 |
| product use in unapproved indicationSignal | 2,945 | 4.0 | 3.9 | 6,671 |
| somnolenceSignal | 2,303 | 3.9 | 3.7 | 4,880 |
| condition aggravatedSignal | 2,364 | 2.6 | 2.5 | 2,378 |
| anxietySignal | 1,829 | 2.2 | 2.1 | 1,148 |
| off label useSignal | 5,623 | 2.2 | 2.1 | 3,627 |
| drug ineffective | 5,251 | 1.3 | 1.3 | 472 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.